{"id":324798,"date":"2022-09-07T01:00:00","date_gmt":"2022-09-06T23:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/nouvelles-options-de-traitement-innovantes\/"},"modified":"2022-09-07T01:00:00","modified_gmt":"2022-09-06T23:00:00","slug":"nouvelles-options-de-traitement-innovantes","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/nouvelles-options-de-traitement-innovantes\/","title":{"rendered":"Nouvelles options de traitement innovantes"},"content":{"rendered":"<p><strong>L&#8217;augmentation de l&#8217;esp\u00e9rance de vie dans le monde s&#8217;accompagne d&#8217;un besoin m\u00e9dical croissant de traitements efficaces contre les maladies cardiovasculaires telles que l&#8217;infarctus du myocarde, l&#8217;accident vasculaire c\u00e9r\u00e9bral et l&#8217;insuffisance cardiaque (IC). De nouveaux m\u00e9dicaments innovants sont d\u00e9sormais disponibles pour lutter contre les maladies cardiovasculaires.&nbsp;<\/strong><strong>et les maladies r\u00e9nales sont disponibles ou en cours de d\u00e9veloppement.<\/strong><\/p>\n<p> <!--more--> <\/p>\n<p>La Commission europ\u00e9enne a accord\u00e9 l&#8217;autorisation de mise sur le march\u00e9 de Finerenon sous la marque Kerendia\u00ae dans l&#8217;Union europ\u00e9enne (UE). Selon une vaste \u00e9tude clinique, il a \u00e9t\u00e9 d\u00e9montr\u00e9 que l&#8217;antagoniste s\u00e9lectif des r\u00e9cepteurs min\u00e9ralocortico\u00efdes (ARM) non st\u00e9ro\u00efdien prot\u00e8ge le c\u0153ur et les reins des patients atteints de maladie r\u00e9nale chronique associ\u00e9e au diab\u00e8te de type 2 en bloquant la suractivation du r\u00e9cepteur min\u00e9ralocortico\u00efde (RM).<\/p>\n<p>La substance active vericiguat (Verquvo\u00ae<sup>)<\/sup> est utilis\u00e9e pour le traitement des adultes souffrant d&#8217;insuffisance cardiaque chronique et de fraction d&#8217;\u00e9jection r\u00e9duite, qui ont r\u00e9cemment re\u00e7u un traitement intraveineux en raison d&#8217;un \u00e9v\u00e9nement de d\u00e9compensation (aggravation soudaine de l&#8217;insuffisance cardiaque). Il a \u00e9t\u00e9 d\u00e9montr\u00e9 que ce m\u00e9dicament r\u00e9duit le risque de d\u00e9c\u00e8s cardiovasculaire et d&#8217;hospitalisation pour cause d&#8217;insuffisance cardiaque et il est autoris\u00e9 pour le traitement de l&#8217;insuffisance cardiaque aux \u00c9tats-Unis, en Europe et au Japon, entre autres.<br \/>\nde l&#8217;entreprise.<\/p>\n<h2 id=\"inhibiteurs-du-facteur-xia-dans-le-pipeline\">Inhibiteurs du facteur XIa dans le pipeline<\/h2>\n<p>Les inhibiteurs de FXIa peuvent devenir une option de traitement pour les patients qui n&#8217;ont pas encore eu la possibilit\u00e9 d&#8217;\u00eatre trait\u00e9s par un anticoagulant. Il s&#8217;agit par exemple de patients souffrant de fibrillation auriculaire et pr\u00e9sentant en m\u00eame temps un risque \u00e9lev\u00e9 d&#8217;h\u00e9morragie. Plusieurs produits prometteurs de cette classe, tels que l&#8217;asundexian, l&#8217;osocimab et le fesomersen, sont en cours de d\u00e9veloppement.<\/p>\n<p><em>Source : Annual Bayer Pharma Media Day 2022<\/em><\/p>\n<p>&nbsp;<\/p>\n<p><em>CARDIOVASC 2022 ; 21(2) : 38<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>L&#8217;augmentation de l&#8217;esp\u00e9rance de vie dans le monde s&#8217;accompagne d&#8217;un besoin m\u00e9dical croissant de traitements efficaces contre les maladies cardiovasculaires telles que l&#8217;infarctus du myocarde, l&#8217;accident vasculaire c\u00e9r\u00e9bral et l&#8217;insuffisance&hellip;<\/p>\n","protected":false},"author":7,"featured_media":123388,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Maladies cardiovasculaires","footnotes":""},"category":[11378,11527,11545,11535,11549],"tags":[12145,14079],"powerkit_post_featured":[],"class_list":["post-324798","post","type-post","status-publish","format-standard","has-post-thumbnail","category-cardiologie","category-etudes","category-marche-medecine","category-rapports-de-congres","category-rx-fr","tag-maladies-cardiovasculaires","tag-options-de-traitement","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-05-05 14:10:01","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":{"it_IT":{"locale":"it_IT","id":324762,"slug":"nuove-opzioni-di-trattamento-innovative","post_title":"Nuove opzioni di trattamento innovative","href":"https:\/\/medizinonline.com\/it\/nuove-opzioni-di-trattamento-innovative\/"},"pt_PT":{"locale":"pt_PT","id":324774,"slug":"novas-opcoes-de-tratamento-inovadoras","post_title":"Novas op\u00e7\u00f5es de tratamento inovadoras","href":"https:\/\/medizinonline.com\/pt-pt\/novas-opcoes-de-tratamento-inovadoras\/"},"es_ES":{"locale":"es_ES","id":324782,"slug":"nuevas-opciones-de-tratamiento-innovadoras","post_title":"Nuevas opciones de tratamiento innovadoras","href":"https:\/\/medizinonline.com\/es\/nuevas-opciones-de-tratamiento-innovadoras\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/324798","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=324798"}],"version-history":[{"count":0,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/324798\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media\/123388"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=324798"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=324798"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=324798"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=324798"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}